Journal of Cardiothoracic and Vascular Anesthesia
Volume 24, Issue 2 , Pages 230-238 , April 2010

Prophylactic Vasopressin in Patients Receiving the Angiotensin-Converting Enzyme Inhibitor Ramipril Undergoing Coronary Artery Bypass Graft Surgery

  • Suruchi Hasija, MD

      Affiliations

    • Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    • ,
  • Neeti Makhija, MD

      Affiliations

    • Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    • Corresponding Author InformationAddress reprint requests to Neeti Makhija, MD, 7th Floor, Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
    • ,
  • Minati Choudhury, MD

      Affiliations

    • Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    • ,
  • Milind Hote, MS, MCh

      Affiliations

    • Department of Cardiothoracic and Vascular Surgery, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    • ,
  • Sandeep Chauhan, MD

      Affiliations

    • Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    • ,
  • Usha Kiran, MD

      Affiliations

    • Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

References 

  1. Sutton MS. Should angiotensin converting enzyme (ACE) inhibitors be used routinely after infarction? (Perspectives from the Survival and Ventricular Enlargement (SAVE) trial). Br Heart J. 1994;71:115–118
  2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure (Collaborative Group on ACE Inhibitor Trials). JAMA. 1995;273:1450–1456
  3. Raja SG, Fida N. Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation?. Interact Cardiovasc Thorac Surg. 2008;7:470–475
  4. Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology. 1994;81:299–307
  5. Augoustides JGT. Angiotensin blockage and general anesthesia: So little known, so far to go. J Cardiothorac Vasc Anesth. 2008;22:177–179
  6. Smith MS, Muir H, Hall R. Perioperative management of drug therapy, clinical considerations. Drugs. 1996;51:238–259
  7. Ryckwaert F, Colson P. Hemodynamic effects of anesthesia in patients with ischemic heart failure chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg. 1997;84:945–949
  8. Mirenda JV, Grissom TE. Anesthetic implications of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. Anesth Analg. 1991;72:667–683
  9. Licker M, Neidhart P, Lustenberger S, et al. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anesthesiology. 1996;84:789–800
  10. Boldt J, Schindler E, Harter K, et al. Influence of intravenous administration of angiotensin-converting enzyme inhibitor enalaprilat on cardiovascular mediators in cardiac surgery patients. Anesth Analg. 1995;80:480–485
  11. Myles PS, Olenikov I, Bujor MA, et al. ACE-inhibitors, calcium antagonists and low systemic vascular resistance following cardiopulmonary bypass (A case-control study). Med J Aust. 1993;158:675–677
  12. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure (SOLVD Investigators). Circulation. 1992;86:431–438
  13. Bottcher M, Behrens JK, Moller EA, et al. ACE inhibitor premedication attenuates sympathetic responses during surgery. Br J Anaesth. 1994;72:633–637
  14. Heropoulos M, Schieren H, Seltzer JL, et al. Intraoperative hemodynamic, renin, and catecholamine responses after prophylactic and intraoperative administration of intravenous enalaprilat. Anesth Analg. 1995;80:583–590
  15. Colson P. Angiotensin-converting enzyme inhibitors. In:  Jones RM,  Aitkenhead AR,  Foex P editor. Clinical Cardiovascular Medicine in Anaesthesia. London: BMJ Publishing Group; 1997;p. 52–73
  16. Tamayo E, Di Stefano S, Carassiti M, et al. Evaluation of the withdrawal of ACE inhibitors in coronary artery surgery. Clin Ter. 2004;155:171–174
  17. Colson P, Ribstein J, Mimran A, et al. Effect of angiotensin converting enzyme inhibition on blood pressure and renal function during open heart surgery. Anesthesiology. 1990;72:23–27
  18. Boldt J, Rothe G, Schindler E, et al. Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery?. Heart. 1996;76:207–213
  19. Hock CE, Ribeiro LG, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J. 1985;109:222–228
  20. Colson P, Saussine M, Seguin JR, et al. Hemodynamic effects of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg. 1992;74:805–808
  21. Yates AP, Hunter DN. Anaesthesia and angiotensin-converting enzyme inhibitors (The effect of enalapril on perioperative cardiovascular stability). Anaesthesia. 1988;43:935–938
  22. Kataja JH, Kaukinen S, Viinamaki OV, et al. Hemodynamic and hormonal changes in patients pretreated with captopril for surgery of the abdominal aorta. J Cardiothorac Anesth. 1989;3:425–432
  23. Thaker U, Geary V, Chalmers P, et al. Low systemic vascular resistance during cardiac surgery: Case reports, brief review, and management with angiotensin II. J Cardiothorac Anesth. 1990;4:360–363
  24. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116:973–980
  25. Tuman KJ, McCarthy RJ, O'Connor CJ, et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995;80:473–479
  26. Oh YJ, Lee JH, Nam SB, et al. Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass. Br J Anaesth. 2006;97:792–798
  27. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125
  28. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg. 2000;69:102–106
  29. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96:286–290
  30. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg. 2003;75:926–930
  31. Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation. 1999;100:226–229
  32. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279–1282
  33. Peach MJ, Cline WH, Watts DT. Release of adrenal catecholamines by angiotensin II. Circ Res. 1966;19:571–575
  34. Khairallah PA. Action of angiotensin on adrenergic nerve endings: Inhibition of norepinephrine reuptake. Fed Proc. 1972;31:1351–1357
  35. Giudicelli JF, Berdeaux A, Edouard A, et al. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol. 1985;20:211–218
  36. Smiley RM, Pantuck CB, Chadburn A, et al. Downregulation and desensitization of the beta-adrenergic receptor system of human lymphocytes after cardiac surgery. Anesth Analg. 1993;77:653–661
  37. Hedner J, Towle A, Saltzman L, et al. Changes in plasma atrial natriuretic peptide immunoreactivity in patients undergoing coronary artery bypass graft placements. Regul Pept. 1987;17:151–157
  38. Pigott DW, Nagle C, Allman K, et al. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth. 1999;83:715–720
  39. Carrel T, Englberger L, Mohacsi P, et al. Low systemic vascular resistance after cardiopulmonary bypass: Incidence, etiology, and clinical importance. J Card Surg. 2000;15:347–353
  40. Salzman AL, Vromen A, Denenberg A, et al. K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol. 1997;272:H688–H694
  41. Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest. 1992;89:2071–2074
  42. Howl J, Wheatley M. Molecular pharmacology of V1a vasopressin receptors. Gen Pharmacol. 1995;26:1143–1152
  43. Kusano E, Tian S, Umino T. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens. 1997;15:627–632
  44. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77:496-499
  45. Talbot MP, Tremblay I, Denault AY, et al. Vasopressin for refractory hypotension during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2000;120:401–402
  46. Licker M, Schweizer A. Vasopressin and postcardiopulmonary bypass refractory hypotension. Anesth Analg. 1999;88:695
  47. Overand PT, Teply JF. Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass. Anesth Analg. 1998;86:1207–1209
  48. Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant. 1999;18:814–817
  49. Albright TN, Zimmerman MA, Selzman CH. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care. 2002;11:326–330
  50. Rosenzweig EB, Starc TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation. 1999;100:II182–II186
  51. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg. 2001;93:7–13
  52. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–582

PII: S1053-0770(09)00300-0

doi: 10.1053/j.jvca.2009.08.001

Journal of Cardiothoracic and Vascular Anesthesia
Volume 24, Issue 2 , Pages 230-238 , April 2010

Article Tools

* Image Usage & Resolution